The European Lung Cancer Congress 2018 (ELCC 2018), is the most important congress in Europe for all clinical practitioners involved in the diagnostic work-up and treatment of lung cancer and other thoracic malignancies.
It brings together a unique community of medical professionals to facilitate the advancement of a personalised approach to the management of lung and other thoracic cancers and the implementation of new discoveries into clinical practice.
Fast facts: ELCC 2018
- Expecting over 2000 international participants
- Specialists and Key Opinion Leaders (KOLs) from all over the world in one place and as one community
- 16 educational, 4 key note, 4 speciality, 4 MIS (Multidisciplinary Interactive Sessions) sessions as well as a variety of different key lectures running over the four days
- An internationally renowned faculty
- 9 Industry Satellite Symposia
- Vibrant commercial exhibition
- Excellent networking opportunities
Past attendance
ESMO gratefully acknowledges the valuable contribution of the following organisations in the ELCC Congresses over the years.
Past attendees | ||
Abbott Laboratories |
Cis Bio International |
Novartis |
AbbVie |
Clovis Oncology |
Olympus Medical Systems Europe |
Agennix |
Daiichi Sankyo Europe |
Otsuka Pharmaceuticals |
Amgen |
Elsevier |
Pfizer Oncology |
Amoy Diagnostics Co. Ltd |
Eli Lilly |
Pfizer Merck Alliance |
Ariad Pharmaceuticals |
GE Healthcare |
PharmaMar, S.A. |
AstraZeneca |
GSK |
Qiagen |
Bayer Schering Pharma |
Helsinn Healthcare |
Roche |
Beacon Oncology Ltd |
Karl Storz |
Rosetta Genomics |
Biocartis |
Merck Serono |
Sanofi |
Boehringer Ingelheim |
Microsulis Medical Ltd. |
Varian Medical Systems |
Bristol-Myers Squibb |
MSD |
Wisepress Ltd |
How can I participate in ELCC 2018?
At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congresses.
Contact the ESMO Events Sponsorship Team for more details. We look forward to hearing from you!